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Since transfusion was introduced, the associated risks, 
including transfusion-transmitted infection and incompat-
ibility, have decreased with improved quality [1]. Although the 
frequency of many complications has decreased, transfusion-
related acute lung injury (TRALI) has become one of the major 
complications associated with transfusion. TRALI is a poten-
tially fatal blood-product transfusion complication that presents 
as acute hypoxemia and noncardiogenic pulmonary edema. 
The first case of TRALI was reported in the 1950s [2]. Al-
though TRALI has been termed a pulmonary hypersensitivity 
reaction, pulmonary infiltrate associated with transfusion reac-
tion, and fulminating noncardiogenic pulmonary edema [3], the 
diagnostic term TRALI was first suggested by Popovsky et al. [4] 
in 1983.
Definition and Epidemiology
TRALI is the leading cause of transfusion-related mortality 
in the United States. TRALI was defined based on clinical and 
radiological parameters at the 2004 Consensus Conference, as 
newly developed acute lung injury (ALI)/acute respiratory dis-
tress syndrome (ARDS) within 6 h of a blood product transfu-
sion (Table 1) [3]. The 6 h time window was chosen based on 
the opinion of an expert panel. Suspected TRALI was defined as 
fulfillment of the definition of TRALI without another ALI risk 
factor. Because the characteristics of TRALI are difficult to dis-
tinguish from those of ALI due to other causes, possible TRALI 
has been suggested to allow for the presence of other ALI risk 
factors. The conventional definition of TRALI included cases 
of ALI that develop within 6 h of transfusion, but transfusion 
is an ALI risk factor for 6–72 h. Thus, delayed TRALI includes 
delayed onset TRALI after transfusion [5].
TRALI occurs in up to 15% of transfused patients [6], but 
other reports estimate the incidence of TRALI at approximately 
0.1% of transfused patients [7,8]. 
Although the true incidence of TRALI is unknown, it is likely 
under-diagnosed and under-estimated, primarily due to poor 
recognition of the disease [8]. Several studies have reported inci-
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dence ranges of 1 in 7,900 units of fresh frozen plasma (FFP) to 
1 in 432 units of whole blood [9,10]. In addition, the incidence 
of TRALI depends on the patient population, and a higher inci-
dence of TRALI is observed in critically ill patients [11]. Histori-
cal estimates for TRALI-associated mortality range from 5 to 8% 
[12], but up to 60% of critically ill patients die from TRALI [13]. 
Risk factors
Specific risk factors for TRALI can be divided conceptually 
into recipient-related risk factors and transfusion-related risk 
factors [14].
Recipient-related risk factors 
Many comorbidities have been suggested as TRALI risk fac-
tors, including end-stage liver disease, coronary artery bypass 
graft, hematological malignancies, massive transfusion, me-
chanical ventilation, sepsis, and heavy alcohol consumption [14]. 
Critical illness is one of the highest risks for TRALI [11,13]. A 
large database review of 11 million elderly patients in the United 
States revealed that TRALI rates are higher in patients receiving 
a transfusion, including platelets or plasma [15]. TRALI inci-
dence increase as the number of units transfused increases. A re-
view also identified that elderly female Caucasians 65–79-years-
old with a 6-month history of post-inflammatory pulmonary 
fibrosis and tobacco use have a greater chance of developing 
TRALI [15].
Transfusion-related risk factors
Immunoglobulin [16] and stem cell preparations [17] are 
also associated with TRALI. A case-control study enrolled 89 
patients with TRALI and 164 controls. The study revealed that 
a higher TRALI odds ratio (OR) is associated with plasma from 
female donors (OR, 4.5; 95% confidence interval [CI], 1.85–11.2) 
and a greater number of transfusions (OR, 4.5; 95% CI, 2.4–8.4).
[18] Blood products including high-plasma-volume (platelet 
concentrates, whole blood, and FFP) have been associated with 
a higher incidence of TRALI [13]. High loading of anti-human 
neutrophil antigen antibody has also been associated with 
TRALI [18]. In contrast, the presence of anti-human leukocyte 
antigen (HLA) class II or anti-HLA class I antibodies is not as-
sociated with TRALI. 
The age of a blood product has been suggested to increase the 
risk for TRALI [19]. Storing red blood cells (RBCs) results in a 
number of morphological and biochemical alterations known as 
RBC storage lesions. However, two studies failed to reveal blood 
age as a risk factor for TRALI [13,18].
Pathogenesis
Two-hit model
A two-hit hypothesis has been suggested for developing 
TRALI [20]. The first hit involves neutrophil sequestration and 
priming in the pulmonary endothelium, which precedes trans-
fusion. Endothelial cells are thought to be responsible for both 
neutrophil sequestration and priming. The second hit is caused 
by activation of the endothelium and neutrophils by media-
tors in the transfused blood, resulting in capillary leakage and 
pulmonary edema. The second hit differs in antibody-mediated 
TRALI and non-antibody-mediated TRALI. Non-antibody-
mediated TRALI is caused by the accumulation of proinflamma-
tory mediators during storage of blood products and possibly by 
ageing of RBCs and platelets [21], whereas antibody-mediated 
TRALI or immune TRALI is caused by passive transfusion of 
HLA or human neutrophil antigen (HNA) and corresponding 
antibodies from the donor directed against recipient antigens 
[22]. Donor anti-leukocyte antibodies interact with recipient 
neutrophils, monocytes, and/or the pulmonary endothelium 
[14]. Bioactive lipids and other factors in transfused blood act 
as biological response modifiers in patients with non-antibody-
mediated TRALI. The proportions of antibody-mediated vs. 
non-antibody-mediated TRALI cases remain unclear. A system-
ic review showed that 86% of TRALI cases are associated with 
leukocyte antibodies [23].
Threshold model
The two-hit hypothesis explains the occurrence of TRALI in 
high-risk patients. However, this hypothesis does not fit TRALI 
that develops in healthy recipients; the threshold model has 
been proposed to explain these cases [24]. This model generally 
agrees that two hits are needed to develop TRALI. However, the 
Table 1. Definition of TRALI
Suspected TRALI
Acute onset within 6 h of blood transfusion
PaO2/FIO2 < 300 mmHg, or worsening of P/F ratio
Bilateral pulmonary infiltrates on chest radiograph
No sign of hydrostatic pulmonary edema (pulmonary arterial occlusion 
pressure ≤ 18 mmHg or central venous pressure ≤ 15 mmHg)
No other risk factor for acute lung injury
Possible TRALI
Same as for suspected TRALI, but another risk factor present for 
acute lung injury
Delayed TRALI
Same as for (possible) TRALI and onset within 6–72 h of blood 
transfusion
PAOP: pulmonary arterial occlusion pressure, CVP: central venous 
pressure, TRALI: transfusion-related acute lung injury.
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threshold model assumes that TRALI can occur when the sec-
ond hit is so strong that an initial priming event is not needed. 
In other words, a large quantity of antibody (second hit) can 
cause TRALI in a recipient with no previous predisposition, 
such as in healthy individuals. 
Clinical presentation and diagnosis
TRALI presents as sudden onset of respiratory difficulties 
during or shortly after transfusion. Hypoxemia and lung infil-
trates are detected on chest X-rays in almost all patients with 
TRALI, and half of patients show a pinkish, frothy sputum [25]. 
Tachypnea, tachycardia, and elevated airway pressure are fre-
quently observed. Fever, hypotension, and cyanosis occur in less 
than one-third of patients with TRALI. 
Confirming hypoxemia, obtaining a chest X-ray, and evaluat-
ing vital signs are required to diagnose TRALI. 
No laboratory test is specific for diagnosing TRALI. The 
greatest change is a transient drop in peripheral neutrophil count 
(possibly due to neutrophil sequestration in the pulmonary vas-
culature). Leucopenia occurs in 35% of patients after transfusion 
with an antibody-containing blood product [26].
TRALI should be distinguished from pulmonary edema 
due to other causes. Hemolytic and septic transfusion reactions 
present similarly to TRALI. Anaphylaxis can cause respiratory 
insufficiency similar to that of TRALI, but airway signs and 
symptoms are more common in patients with anaphylaxis. ALI/
ARDS should be distinguished from TRALI in patients with risk 
factors for ALI/ARDS prior to a transfusion.
Transfusion-associated circulatory overload (TACO) is another 
cause of transfusion-related respiratory insufficiency (Table 2) 
[27]. Impaired myocardial function and rapid and aggressive 
fluid therapy are suggested risk factors for TACO. TRALI is 
more likely to be associated with signs and symptoms of inflam-
mation, including fever, hypotension, and an exudative pulmo-
nary infiltrate. In contrast, TACO is more likely to be associated 
with findings suggestive of cardiac dysfunction and/or volume 
overload.
Treatment
No specific treatment exists for this syndrome. Corticoste-
roids have been used for ALI/ARDS, but the results are incon-
sistent. Routine use of corticosteroids in patients with TRALI is 
not advocated, although a successful case has been reported [28].
The transfusion should be stopped immediately if TRALI 
is suspected. The blood bank should be notified of the event to 
initiate a transfusion reaction evaluation to protect further un-
expected victims.
Management of TRALI is supportive. Providing oxygen 
supple mentation is the central management approach for hy-
poxemia. Limited evidence is available for managing patients 
with TRALI using mechanical ventilation [29], and it is logical 
to apply a lower tidal volume in patients with ARDS from other 
causes. There is a case report of applying extracorporeal mem-
brane oxygenation in a patient with severe TRALI [30]. 
Prognosis and prevention
Mortality due to TRALI is 5–10%, in contrast to ARDS [31]. 
However, 90-day mortality associated with TRALI can reach 
47% in critically ill populations [13]. Long-term pulmonary 
function in TRALI survivors seems to be similar to that of pa-
tients who have never experienced TRALI, and no apparent late 
complications, such as fibrosis or other structural damage to the 
lung parenchyma occur as a result of TRALI [13]. The clinical 
course of patients with TRALI is suggested by quick resolution 
(~2 days) of hypoxemia.
Cases suspected of TRALI should be promptly reported to 
the blood bank. The blood bank should investigate all associated 
donors for the presence of anti-HLA and anti-HNA antibodies 
to identify donors with these antibodies and prevent them from 
future donation. This is particularly true if the donor has anti-
HNA 3a [32].
In addition, several general blood donor management strate-
gies are in use to reduce the incidence of TRALI [32-38]. First, 
adherence to current guidelines for utilizing blood components, 
particularly those for plasma, is mandatory to decrease exposure 
risk for patients. A restrictive transfusion strategy has been asso-
ciated with a lower incidence of TRALI compared with that of a 
liberal transfusion strategy [39]. Clifford et al. [40] reported that 
patients transfused with greater volumes of blood components 
develop perioperative TRALI/possible TRALI more frequently 
than that reported previously. He reported that the overall in-
cidence of TRALI was 22.46 per 100,000 stays. Optimal trans-
fusion guidelines should provide sufficient blood products to 
Table 2. Distinguishing TRALI from TACO
        TRALI       TACO
Blood pressure
Body temperature
CXR
BNP
PAOP
Ejection fraction
Response to diuretics
Edema fluid
Low-normal
Normal-elevated
No vascular congestion
Low (< 250 pg/ml)
Low-normal
Normal function
Inconsistent
Transudate
Normal-high
Normal
Vascular congestion, 
  pleural effusion
High
High
Abnormal function
Improved
Exudate
TRALI: transfusion-related acute lung injury, TACO: transfusion-
associated cardiac overload, CXR: chest X-ray, BNP: B type natriuretic 
peptide, PAOP: pulmonary artery occluding pressure.
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maximize clinical outcomes while avoiding adverse events, such 
as TRALI. However, no golden transfusion guidelines exist for 
all patients. Clinicians should consider many factors when de-
ciding to transfuse anemic patients, rather than basing the deci-
sion solely on a specified laboratory level. In this respect, Carson 
et al. [41] demonstrated that liberal blood transfusion approach 
with a hemoglobin concentration threshold of 90–100 g/L does 
not affect mortality in a high-risk group of elderly patients with 
underlying cardiovascular disease or risk factors, compared with 
that of a restrictive transfusion strategy with a hemoglobin con-
centration threshold of 70–80 g/L. Therefore, the final decision 
to transfuse should incorporate the patient’s clinical condition, 
co-morbidities, and the individual wishes of the patient. Second, 
donors with little chance to be alloimmunized to leukocytes 
should receive high plasma volume components (e.g., FFP, 
plasma frozen within 24 h of phlebotomy [FP-24], plasma, cryo-
reduced plasma, apheresis platelets, or whole blood). Third, use 
pooled solvent detergent-treated plasma as an alternative to FFP. 
Fourth, test for anti-HLA antibodies in pregnant donors before 
apheresis of platelets or plasma. In particular, several manage-
ment strategies including deferral of multiparous female donors 
are in use to reduce the incidence of TRALI [42].
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